# Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

> **NCT03597516** · PHASE3 · COMPLETED · sponsor: **Ritter Pharmaceuticals, Inc.** · enrollment: 557 (actual)

## Conditions studied

- Lactose Intolerance

## Interventions

- **DRUG:** RP-G28
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03597516
- **Lead sponsor:** Ritter Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-26
- **Primary completion:** 2019-07-02
- **Final completion:** 2019-07-02
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2019-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03597516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03597516, "Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03597516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*